Amgen Return on Equity (ROE) Growth & History (AMGN)

Amgen's return on equity was 106.10% for fiscal 2025.

View full Amgen company overview

Amgen annual return on equity history

Amgen annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20252025-12-31106.10%+38.55 pp
20242024-12-3167.55%−68.24 pp
20232023-12-31135.79%+9.32 pp
20222022-12-31126.47%+53.31 pp
20212021-12-3173.16%−2.97 pp
20202020-12-3176.13%+5.40 pp
20192019-12-3170.73%+26.25 pp
20182018-12-3144.48%+37.30 pp
20172017-12-317.18%−19.47 pp
20162016-12-3126.65%+0.88 pp
20152015-12-3125.77%+4.22 pp
20142014-12-3121.55%−3.14 pp
20132013-12-3124.69%+1.88 pp
20122012-12-3122.81%+5.67 pp
20112011-12-3117.14%−2.71 pp
20102010-12-3119.85%−1.29 pp
20092009-12-3121.15%+0.58 pp
20082008-12-3120.57%

Amgen return on equity trends

Over the last five fiscal years, Amgen's return on equity increased from 76.13% to 106.10%, a change of +29.97 percentage points. The latest reported quarter, Q2 2026, shows 22.75%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Amgen source filings ↗

Community posts

It’s quiet here.

No posts about AMGN yet. Start the conversation.

Write the first post